Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib and Trastuzumab with AI in HER2+ HR+ MBC (ALTERNATIVE)
NCT01160211Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2011
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of lapatinib in breast cancer, sponsored by Novartis. Started May 2011; status: completed.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01160211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01160211.